Proactive Investors - Run By Investors For Investors

ImmuPharma phase III clinical trial remains on track; over half the patients have now completed the study

In all, 116 of the 200 patients with the life-threatening auto-immune disease have been through the 52-week process looking at the efficacy of Lupuzor
test tubes filled with blood
The top-line results from the phase III study should be available in the first quarter of next year

ImmuPharma PLC (LON:IMM) confirmed it is on track to publish top-line results from its phase III clinical trial in the first quarter of next year after it said over half the group had completed the full 12-month study assessing the performance of its potentially breakthrough treatment for lupus.

In all,116 of the 200 patients with the life-threatening auto-immune disease have been through the 52-week process looking at the efficacy of Lupuzor; all are now at or past the nine-month stage.

WATCH: Immupharma 'looking forward and planning for success' with Lupuzor

The phase III trial is what’s called a randomised, double-blind investigation, which means half the group will have been administered the ImmuPharma drug, while the others will have received a placebo that has no impact on the condition.

The doctors running the study will only know which group is which once the whole process is concluded.

At this stage they do know Lupuzor’s “robust” safety record remains consistent with what was seen at the successful phase IIb stage.

"The trial continues to progress on track and on time,” said chairman Tim McCarthy.

Debilitating disease

Systemic Lupus Erythematosus (SLE) is a debilitating and painful disease, which sees the body's immune system turn against itself for reasons still not fully understood.

It can affect various organs in various people in various ways so many symptoms can ensue, which calls for treatment from heart, liver and skin specialists.

READ: Immupharma starts preparations for Lupuzor submission as trial makes good progress

The shares, up 84% in the year to date, marked time at 95p. City broker Northland reckons the stock is worth 185p.

“Should Lupuzor successfully meet the trial endpoints, we estimate that ImmuPharma’s shares would significantly rerate to the upside,” said analyst Vadim Alexandre.

It is much more common in women, appears most often in African-Americans, Asians and Hispanics and it is estimated that up to five million individuals worldwide may be affected.

ImmuPharma does not claim Lupuzor is a cure but hopes it will offer significant relief to sufferers such that their quality of life is greatly improved.

It also thought to be more effective than other products available, such as Glaxo's Benlysta.

View full IMM profile View Profile

ImmuPharma PLC Timeline

Related Articles

November 29 2018
The deal with New England Biolabs, signed in October, is expected to secure six-figure royalty sums as soon as next year
man coughing
November 09 2018
Some of the big boys are shifting their focus away from their respiratory drugs, which could open up opportunities for Circassia to in-license them
test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use